Ameriprise’s Humacyte HUMA Stock Holding History

Ameriprise’s Portfolio HUMA Stock Details HUMA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-11,530	Closed	-$19.7K	–	4041
2025 Q1	$19.7K	Sell	11,530 -25	-0.2%	-$94	﹤0.01%	3984
2024 Q4	$58.4K	Buy	+11,555	New	+$57.2K	﹤0.01%	3997

Other funds holding HUMA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

CenterBook Partners Greenwich, Connecticut $1.86B AUM 24.52% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Ameriprise's HUMA Position: Q2 2025 in Review

Ameriprise sold out of Humacyte (HUMA) in Q2 2025, closing a stake of 11,530 shares — an estimated $19.7K sold.

Ameriprise first reported a position in HUMA in Q4 2024 and held it in 2 quarters. The position peaked at $58.4K in Q4 2024. 156 funds tracked by Wall St. Rank hold HUMA as of Q2 2025.

Ameriprise reported no remaining Humacyte position as of Q2 2025 after selling out during the quarter.
Ameriprise sold 11,530 Humacyte shares in Q2 2025, an estimated $19.7K.
Ameriprise first reported a position in Humacyte in Q4 2024 and held it in 2 quarters.
Ameriprise's Humacyte position peaked at $58.4K in Q4 2024.
156 funds tracked by Wall St. Rank held Humacyte as of Q2 2025.

Based on Ameriprise's 13F filing for Q2 2025, filed 14 Aug 2025.